CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Codiak BioSciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Codiak BioSciences Inc
35 CambridgePark Drive, Suite 500
Phone: (617) 949-4100p:617 949-4100 CAMBRIDGE, MA  02140  United States Fax: (302) 655-5049f:302 655-5049
This entity represents the bankrupt estate of the former businesses (assets) of Codiak BioSciences, Inc. that were not sold to Evox Therapeutics Ltd. and Astellas Institute for Regenerative Medicine on 6/12/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx exosomes), focused on treating a range of diseases, including oncology, rare disease and infectious disease. Its product candidates include exoSTING, exoIL-12 and exoASO-STAT6. exoSTING is an exosome therapeutic candidate engineered with its engEx Platform to incorporate its stimulator of interferon genes (STING) agonist inside the lumen of the exosome. exoIL-12 is an exosome therapeutic candidate engineered using its engEx Platform to display IL-12 in a fully active form on the surface via its scaffold protein, prostaglandin F2 receptor negative regulator (PTGRFN).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYesYes--

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board StevenGillis 70 11/1/2015 11/1/2015
Chief Financial Officer, Treasurer Linda C.Bain 12/1/2015 12/1/2015
Chief Technology Officer KonstantinKonstantinov 64 6/15/2021 1/1/2019
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Codiak BioSciences Inc
Codiak Securities Corporation
Codiak Securities Corporation

General Information
Outstanding Shares: 36,829,626 (As of 10/27/2022)
Shareholders: 17
Stock Exchange: OTC
Federal Tax Id: 474926530
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 6, 2024